Enfortumab vedotin with pembrolizumab for untreated unresectable or metastatic urothelial cancer when platinum-based chemotherapy is suitable

Technology appraisal guidance
Reference number: TA1097
Published: 11 September 2025

NIHRIO BN: Microsoft Word - 29564 (TSID_10556) Enfortumab vedotin+Pembrolizumab for UC V1.0 NOV22 NON CONF (nihr.ac.uk)

This page was last updated: 02 November 2023